Welcome to our dedicated page for Springworks Therapeutics news (Ticker: SWTX), a resource for investors and traders seeking the latest updates and insights on Springworks Therapeutics stock.
SpringWorks Therapeutics, Inc. (SWTX) is a clinical-stage biopharmaceutical company pioneering targeted therapies for rare diseases and oncology. This news hub provides investors and healthcare professionals with essential updates on therapeutic advancements, regulatory milestones, and strategic collaborations.
Access authoritative information on SWTX's precision medicine pipeline, including FDA communications, clinical trial developments, and partnership announcements. Our curated collection features:
• Regulatory updates on approved therapies and review timelines
• Clinical trial progress across rare disease and oncology programs
• Research collaborations with academic institutions and industry leaders
• Scientific presentations at major medical symposiums
Bookmark this page for real-time access to verified SWTX developments. For comprehensive analysis of the company's therapeutic pipeline and market position, visit regularly for the latest updates directly from primary sources.
SpringWorks Therapeutics (Nasdaq: SWTX) announced that CEO Saqib Islam will present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 8:15 am ET. A video webcast of the event will be available on the company's Investors & Media section of their website, with a replay accessible afterward. SpringWorks focuses on developing medicines for severe rare diseases and cancer, with 17 development programs in progress, including two late-stage clinical trials.
SpringWorks Therapeutics (SWTX) has announced a clinical collaboration with AbbVie to study nirogacestat in combination with ABBV-383 for treating relapsed or refractory multiple myeloma. This marks the seventh BCMA collaboration for SpringWorks. AbbVie will sponsor the Phase 1b study, covering all costs except for nirogacestat manufacturing and certain intellectual property expenses. Nirogacestat has shown promise in preclinical studies by enhancing the effectiveness of BCMA-targeted therapies. The study is set to begin in the first half of 2022.
SpringWorks Therapeutics (Nasdaq: SWTX) has initiated a Phase 1b/2 trial for nirogacestat, a gamma secretase inhibitor, alongside Pfizer's elranatamab for treating relapsed or refractory multiple myeloma. The trial aims to assess safety, tolerability, and preliminary efficacy. Preclinical studies indicate that nirogacestat may enhance BCMA-targeted therapies by increasing BCMA density on myeloma cells. This collaboration with Pfizer also includes a joint development approach, intending to improve treatment options for patients.
SpringWorks Therapeutics (Nasdaq: SWTX) has announced the full enrollment of its Phase 2b ReNeu trial, which evaluates mirdametinib, a MEK inhibitor, for treating NF1-associated plexiform neurofibromas (NF1-PN) in adults and children. Over 50 adults and 50 pediatric patients have been enrolled. The trial will assess the drug's efficacy, safety, and tolerability with a primary endpoint of a ≥ 20% tumor volume reduction. Interim data showed promising results, with 50% of the initial patients responding positively to treatment. The company plans to share further updates at an upcoming R&D Day.
SpringWorks Therapeutics, Inc. (Nasdaq: SWTX) will participate in a Fireside Chat at the 4th Annual Evercore ISI HealthCONx Conference on November 30, 2021, at 3:30 pm ET. The event will be held virtually, and a video webcast can be accessed through the company’s Investors & Media page. SpringWorks specializes in developing medicines for severe rare diseases and cancer, with 16 development programs and two advanced product candidates in late-stage clinical trials. For further details, visit SpringWorks’ website.
SpringWorks Therapeutics (SWTX) reported significant advancements in its oncology pipeline, including progression to randomized Phase 2 studies for nirogacestat in patients with relapsed multiple myeloma. The company also expanded its oncology portfolio with the in-licensing of next-generation EGFR inhibitors, initiated a Phase 1/2 study for mirdametinib in breast cancer, and secured new patents extending protection until 2041. Financially, R&D expenses rose to $22.9 million and G&A expenses increased to $18 million, contributing to a net loss of $41 million for Q3 2021.
SpringWorks Therapeutics (SWTX) has announced the initiation of a randomized Phase 2 cohort expansion study exploring the combination of BLENREP (0.95 mg/kg Q3W) with nirogacestat in patients with relapsed/refractory multiple myeloma. This follows positive preliminary data from earlier trials. Additionally, two new sub-studies are planned to assess this combination with standard therapies. The company continues to focus on nirogacestat’s potential as a cornerstone therapy, collaborating closely with GlaxoSmithKline amidst ongoing evaluations in various clinical studies.
SpringWorks Therapeutics (SWTX) announced a collaboration with Ab Magnitude Ventures to develop next-generation targeted oncology therapeutics. This partnership leverages the expertise of Yibing Shan, Ph.D., in computational modeling to enhance drug discovery capabilities, focusing on optimizing a newly licensed portfolio of EGFR inhibitors. SpringWorks aims to advance its early-stage pipeline by integrating advanced computational techniques into its drug development efforts. Under the agreement, Ab Magnitude may receive low single-digit percentage royalties on future sales.
SpringWorks Therapeutics (Nasdaq: SWTX) announced a licensing agreement with Dana-Farber Cancer Institute for novel small molecule inhibitors targeting EGFR mutations in lung cancer. This portfolio, developed at Stanford Medicine, aims to address resistance mutations, notably the C797S mutation. SpringWorks will provide an upfront payment and may owe future milestones and royalties. Additionally, they entered a multi-year Sponsored Research Agreement to support ongoing research at Stanford and Dana-Farber. The company's strategy focuses on precision medicine and targeted therapies for solid tumors.
SpringWorks Therapeutics (Nasdaq: SWTX) announced its participation in the H.C. Wainwright 23rd Annual Global Investment Conference. The management presentation will be available on-demand starting September 13, 2021, at 7:00 am ET. Interested parties can access the webcast via the 'Events & Presentations' section on the company’s website. SpringWorks is focused on developing medicines for severe rare diseases and cancers, with a portfolio that includes 15 development programs and two lead candidates in late-stage clinical trials.
